Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib for Pulmonary Arterial Hypertension
Recruiting1 awardPhase 1 & 2
Edmonton, Alberta
This trial will test if a drug that has been approved for ovarian cancer is also safe to use for pulmonary arterial hypertension and if it is effective in treating the disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.